Glucose: A vital toxin and potential utility of melatonin in protecting against the diabetic state


KORKMAZ A., Ma S., Topal T., Rosales-Corral S., Tan D., Reiter R. J.

Molecular and Cellular Endocrinology, cilt.349, sa.2, ss.128-137, 2012 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 349 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/j.mce.2011.10.013
  • Dergi Adı: Molecular and Cellular Endocrinology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.128-137
  • Anahtar Kelimeler: Hyperglycemia, Insulin resistance, Diabetes, Melatonin
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

The molecular mechanisms including elevated oxidative and nitrosative reactants, activation of pro-inflammatory transcription factors and subsequent inflammation appear as a unified pathway leading to metabolic deterioration resulting from hyperglycemia, dyslipidemia, and insulin resistance. Consistent evidence reveals that chronically-elevated blood glucose initiates a harmful series of processes in which toxic reactive species play crucial roles. As a consequence, the resulting nitro-oxidative stress harms virtually all biomolecules including lipids, proteins and DNA leading to severely compromised metabolic activity. Melatonin is a multifunctional indoleamine which counteracts several pathophysiologic steps and displays significant beneficial effects against hyperglycemia-induced cellular toxicity. Melatonin has the capability of scavenging both oxygen and nitrogen-based reactants and blocking transcriptional factors which induce pro-inflammatory cytokines. These functions contribute to melatonin's antioxidative, anti-inflammatory and possibly epigenetic regulatory properties. Additionally, melatonin restores adipocyte glucose transporter-4 loss and eases the effects of insulin resistance associated with the type 2 diabetic state and may also assist in the regulation of body weight in these patients. Current knowledge suggests the clinical use of this non-toxic indoleamine in conjunction with other treatments for inhibition of the negative consequences of hyperglycemia for reducing insulin resistance and for regulating the diabetic state. © 2011 Elsevier Ireland Ltd.